{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:52Z","timestamp":1792510132271,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07887-0","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:27:54Z","timestamp":1768901274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fracture risk in metastatic breast cancer patients treated with CDK 4\/6 inhibitors and endocrine therapy"],"prefix":"10.1007","volume":"215","author":[{"given":"Rebecca","family":"Pedersini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Schivardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Baluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Zamparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Brentegani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Buizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scartabellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pellicioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"7887_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac234","author":"M Toi","year":"2023","unstructured":"Toi M, Boyle F, Im YH et al (2023) Adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarchE cohort 1. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyac234","journal-title":"Oncologist"},{"key":"7887_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"7887_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"7887_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P et al (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585","journal-title":"J Clin Oncol"},{"key":"7887_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"key":"7887_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911149","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S et al (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1911149","journal-title":"N Engl J Med"},{"key":"7887_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"7887_CR8","doi-asserted-by":"crossref","unstructured":"Hirbe A, Morgan EA, Ulu\u00e7kan \u00d6, et al (2006) Skeletal complications of breast cancer therapies. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-06-0652"},{"key":"7887_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199612123352401","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. https:\/\/doi.org\/10.1056\/nejm199612123352401","journal-title":"N Engl J Med"},{"key":"7887_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.3.846","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.1999.17.3.846","journal-title":"J Clin Oncol"},{"key":"7887_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs003","author":"K Siggeirsdottir","year":"2012","unstructured":"Siggeirsdottir K, Aspelund T, Jonsson BY et al (2012) Effect of vertebral fractures on function, quality of life and hospitalisation the AGES-Reykjavik study. Age Ageing. https:\/\/doi.org\/10.1093\/ageing\/afs003","journal-title":"Age Ageing"},{"key":"7887_CR12","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1997.12.1.152","author":"H Burger","year":"1997","unstructured":"Burger H, Van Daele PLA, Grashuis K et al (1997) Vertebral deformities and functional impairment in men and women. J Bone Miner Res. https:\/\/doi.org\/10.1359\/jbmr.1997.12.1.152","journal-title":"J Bone Miner Res"},{"key":"7887_CR13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-10-199805150-00001","author":"MC Nevitt","year":"1998","unstructured":"Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. https:\/\/doi.org\/10.7326\/0003-4819-128-10-199805150-00001","journal-title":"Ann Intern Med"},{"key":"7887_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2017.03.001","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ et al (2017) Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001","journal-title":"J Bone Oncol"},{"key":"7887_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70003-7","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(07)70003-7","journal-title":"Lancet Oncol"},{"key":"7887_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0726","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2007.11.0726","journal-title":"J Clin Oncol"},{"key":"7887_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu103","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M et al (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdu103","journal-title":"Ann Oncol"},{"key":"7887_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/03008916231216830","author":"S Nardin","year":"2024","unstructured":"Nardin S, Ruelle T, Giannubilo I, Del Mastro L (2024) Adjuvant treatment in hormone receptor-positive early breast cancer: new approaches of endocrine therapy. Tumori. https:\/\/doi.org\/10.1177\/03008916231216830","journal-title":"Tumori"},{"key":"7887_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231178125","author":"DJ Slamon","year":"2023","unstructured":"Slamon DJ, Fasching PA, Hurvitz S et al (2023) Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2\u2212 early breast cancer. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231178125","journal-title":"Ther Adv Med Oncol"},{"key":"7887_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. https:\/\/doi.org\/10.1016\/j.ijsu.2014.07.013","journal-title":"Int J Surg"},{"key":"7887_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650080915","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"7887_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00749-5","author":"FM Ulivieri","year":"2020","unstructured":"Ulivieri FM, Rinaudo L, Piodi LP et al (2020) Usefulness of dual X-ray absorptiometry-derived bone geometry and structural indexes in mastocytosis. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-020-00749-5","journal-title":"Calcif Tissue Int"},{"key":"7887_CR23","doi-asserted-by":"publisher","first-page":"E2350950","DOI":"10.1001\/jamanetworkopen.2023.50950","volume":"7","author":"D Cosentini","year":"2024","unstructured":"Cosentini D, Pedersini R, Di Mauro P et al (2024) Fat body mass and vertebral fracture progression in women with breast cancer. JAMA Netw Open 7:E2350950. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50950","journal-title":"JAMA Netw Open"},{"key":"7887_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-024-07254-y","author":"K Akeda","year":"2024","unstructured":"Akeda K, Nakase K, Yamada J et al (2024) Progression of vertebral deformity of prevalent vertebral fractures in the elderly: a population-based study. BMC Musculoskelet Disord. https:\/\/doi.org\/10.1186\/s12891-024-07254-y","journal-title":"BMC Musculoskelet Disord"},{"key":"7887_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01696","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.01696","journal-title":"J Clin Oncol"},{"key":"7887_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4704-5","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"7887_CR27","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/hae.13611","volume":"24","author":"FM Ulivieri","year":"2018","unstructured":"Ulivieri FM, Rebagliati GAA, Piodi LP et al (2018) Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients. Haemophilia 24:980\u2013987. https:\/\/doi.org\/10.1111\/hae.13611","journal-title":"Haemophilia"},{"key":"7887_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4614","author":"C Van Poznak","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE et al (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical oncology-cancer care Ontario focused guideline update. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2017.75.4614","journal-title":"J Clin Oncol"},{"key":"7887_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104502","author":"R Scafetta","year":"2025","unstructured":"Scafetta R, Donato M, Gullotta C et al (2025) Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4\/6 inhibitors. Breast. https:\/\/doi.org\/10.1016\/j.breast.2025.104502","journal-title":"Breast"},{"key":"7887_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.04.003","author":"GG Crans","year":"2005","unstructured":"Crans GG, Genant HK, Krege JH (2005) Prognostic utility of a semiquantitative spinal deformity index. Bone. https:\/\/doi.org\/10.1016\/j.bone.2005.04.003","journal-title":"Bone"},{"key":"7887_CR31","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1200\/JCO.20.00434","volume":"38","author":"A Dalla Volta","year":"2020","unstructured":"Dalla Volta A, Mazziotti G, Maffezzoni F et al (2020) Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies. J Clin Oncol Off J Am Soc Clin Oncol 38:3363\u20133366. https:\/\/doi.org\/10.1200\/JCO.20.00434","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7887_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11080","author":"R Pedersini","year":"2019","unstructured":"Pedersini R, Amoroso V, Maffezzoni F et al (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11080","journal-title":"JAMA Netw Open"},{"key":"7887_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01447-9","author":"A Dalla Volta","year":"2023","unstructured":"Dalla Volta A, Caramella I, Di Mauro P et al (2023) Role of body composition in the prediction of skeletal fragility induced by hormone deprivation therapies in cancer patients. Curr Oncol Rep. https:\/\/doi.org\/10.1007\/s11912-023-01447-9","journal-title":"Curr Oncol Rep"},{"key":"7887_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052477","author":"M Iuliani","year":"2022","unstructured":"Iuliani M, Simonetti S, Ribelli G et al (2022) Biological effects of cyclin-dependent kinase inhibitors ribociclib, palbociclib and abemaciclib on breast cancer bone microenvironment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23052477","journal-title":"Int J Mol Sci"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07887-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07887-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:09:36Z","timestamp":1770034176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07887-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7887"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07887-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"58"}}